Clinical Trial Update: Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial tested EBV-specific T cells for relapsed/refractory EBV-positive lymphomas and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• EBV-specific T cells

Snippet

Sponsor: Queensland Institute of Medical Research | Conditions: Lymphoma | Phase 1 | Status: COMPLETED